Equities Analysts Issue Forecasts for Conatus Pharmaceuticals’ FY2021 Earnings (CNAT)

Conatus Pharmaceuticals (NASDAQ:CNAT) – Investment analysts at SunTrust Banks decreased their FY2021 earnings estimates for shares of Conatus Pharmaceuticals in a research note issued to investors on Wednesday, April 4th. SunTrust Banks analyst J. Boris now anticipates that the biotechnology company will earn $2.25 per share for the year, down from their prior forecast of $2.44. SunTrust Banks currently has a “Buy” rating and a $4.30 price target on the stock.

How to Become a New Pot Stock Millionaire

CNAT has been the topic of a number of other research reports. Zacks Investment Research lowered Conatus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, January 22nd. S&P Equity Research raised their price objective on Conatus Pharmaceuticals from $5.02 to $5.69 in a report on Wednesday, January 24th. Oppenheimer set a $14.00 price objective on Conatus Pharmaceuticals and gave the company a “buy” rating in a report on Thursday. HC Wainwright restated a “buy” rating and issued a $17.00 price objective on shares of Conatus Pharmaceuticals in a report on Thursday, March 8th. Finally, ValuEngine lowered Conatus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday. Two investment analysts have rated the stock with a sell rating and seven have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $12.00.

Shares of CNAT stock opened at $4.03 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.82 and a current ratio of 2.82. The firm has a market capitalization of $180.66, a price-to-earnings ratio of -6.61 and a beta of 1.16. Conatus Pharmaceuticals has a fifty-two week low of $3.85 and a fifty-two week high of $9.40.

Conatus Pharmaceuticals (NASDAQ:CNAT) last announced its quarterly earnings data on Wednesday, March 7th. The biotechnology company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.02. The company had revenue of $8.80 million for the quarter, compared to analyst estimates of $9.60 million. Conatus Pharmaceuticals had a negative return on equity of 61.58% and a negative net margin of 49.17%.

Several hedge funds and other institutional investors have recently bought and sold shares of CNAT. State Street Corp purchased a new position in shares of Conatus Pharmaceuticals during the 2nd quarter worth $2,092,000. California State Teachers Retirement System purchased a new position in shares of Conatus Pharmaceuticals during the 2nd quarter worth $261,000. New York State Common Retirement Fund raised its holdings in shares of Conatus Pharmaceuticals by 156.4% during the 3rd quarter. New York State Common Retirement Fund now owns 24,100 shares of the biotechnology company’s stock worth $132,000 after acquiring an additional 14,700 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Conatus Pharmaceuticals by 41.2% during the 3rd quarter. Bank of New York Mellon Corp now owns 184,021 shares of the biotechnology company’s stock worth $1,010,000 after acquiring an additional 53,678 shares during the period. Finally, Macquarie Group Ltd. purchased a new position in shares of Conatus Pharmaceuticals during the 3rd quarter worth $330,000. Institutional investors and hedge funds own 39.49% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was originally published by Ticker Report and is owned by of Ticker Report. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3337019/equities-analysts-issue-forecasts-for-conatus-pharmaceuticals-fy2021-earnings-cnat.html.

About Conatus Pharmaceuticals

Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.

Earnings History and Estimates for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Contrasting Post  & General Mills
Contrasting Post & General Mills
Critical Analysis: Biocept  and Its Competitors
Critical Analysis: Biocept and Its Competitors
Rolls-Royce Holdings plc  to Issue Dividend of GBX 7.10
Rolls-Royce Holdings plc to Issue Dividend of GBX 7.10
Zacks: Quanterix Corp.  Given $25.67 Average Price Target by Analysts
Zacks: Quanterix Corp. Given $25.67 Average Price Target by Analysts
Michael Kors Holdings  CEO John D. Idol Sells 150,000 Shares
Michael Kors Holdings CEO John D. Idol Sells 150,000 Shares
MicroStrategy  Upgraded at BidaskClub
MicroStrategy Upgraded at BidaskClub


© 2006-2018 Ticker Report. Google+.